Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about TF: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
AI-generated illustration · click image to enlarge
Regenerate portrait ↻| Gene Symbol | TF |
| Full Name | Transferrin |
| Chromosome | 3q22.1 |
| Function | is a single-chain glycoprotein folded into two homologous lobes (N-lobe and C-lobe), each containing a single iron-binding site. |
| Molecular Weight | 80 kDa |
| Pathways | Iron uptake |
| UniProt ID | P02787 |
| NCBI Gene ID | 7018 |
| OMIM | 190000 |
| GeneCards | TF |
| Human Protein Atlas | TF |
| TfR1 dysregulation | TfR1 expression is altered in AD neurons, potentially increasing iron uptake into vulnerable cells.[@zecca2004] |
| Associated Diseases | neurodegeneration |
| Interactions | MYC, OCT4, TP53, WNT |
| KG Connections | 29 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
Knowledge base pages for this entity
graph TD
TF["TF"]
Iron["Iron"]
TFRC["TFRC"]
TFR2["TFR2"]
Chronic_Cerebral_Hypoperfusion["Chronic Cerebral Hypoperfusion"]
neurodegeneration["neurodegeneration"]
TF -->|"binds"| Iron
TFRC -->|"binds"| TF
TFR2 -->|"binds"| TF
Chronic_Cerebral_Hypoperfusion -->|"upregulates"| TF
TF -->|"implicated in"| neurodegeneration
style TF fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#fff
style Iron fill:#1a1a2e,stroke:#888,stroke-width:2px,color:#fff
style TFRC fill:#1a1a2e,stroke:#888,stroke-width:2px,color:#fff
style TFR2 fill:#1a1a2e,stroke:#888,stroke-width:2px,color:#fff
style Chronic_Cerebral_Hypoperfusion fill:#1a1a2e,stroke:#888,stroke-width:2px,color:#fff
style neurodegeneration fill:#1a1a2e,stroke:#888,stroke-width:2px,color:#fff| Target | Relation | Type | Str |
|---|---|---|---|
| Iron | binds | compound | 0.95 |
| Iron uptake | involved_in | process | 0.90 |
| TFR2 | upregulates | protein | 0.80 |
| oxidative stress response | participates_in | pathway | 0.70 |
| pyroptosis | participates_in | pathway | 0.60 |
| ubiquitin-proteasome | participates_in | pathway | 0.60 |
| microglia | expressed_in | cell_type | 0.60 |
| astrocytes | expressed_in | cell_type | 0.60 |
| WNT | inhibits | gene | 0.60 |
| Alzheimer's disease | inhibits | disease | 0.60 |
| NF-kB signaling | participates_in | pathway | 0.60 |
| TP53 | inhibits | gene | 0.60 |
| TXNIP | regulates | gene | 0.60 |
| neurons | expressed_in | cell_type | 0.55 |
| Source | Relation | Type | Str |
|---|---|---|---|
| Chronic Cerebral Hypoperfusion | upregulates | process | 0.85 |
| DNA | co_expressed_with | gene | 0.60 |
| MYC | inhibits | gene | 0.60 |
| SPI1 | regulates | gene | 0.60 |
| OCT4 | activates | gene | 0.60 |
| FOXO | regulates | gene | 0.60 |
| APOE | regulates | gene | 0.60 |
| FOS | regulates | gene | 0.60 |
| JUN | regulates | gene | 0.60 |
| CCND1 | regulates | gene | 0.60 |
| MYH9 | regulates | gene | 0.60 |
| AXIN1 | regulates | gene | 0.60 |
| MYO1C | regulates | gene | 0.60 |
| RHEB | regulates | gene | 0.60 |
| SOCS3 | regulates | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neurodegeneration | 2026-04-11 | 0 hypotheses
molecular biology | 2026-04-11 | 0 hypotheses
molecular biology | 2026-04-10 | 0 hypotheses
neurodegeneration | 2026-04-08 | 3 hypotheses Top: 0.470
neurodegeneration | 2026-04-07 | 4 hypotheses Top: 0.705
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| IRI-AKI mouse model with mtROS inhibition | validation | ischemic acute kidney injury | 0.900 | 0.00 | IRI-AKI mice | proposed | N/A |
| mtROS effects on TFAM and mtDNA in HK2 cells | exploratory | acute kidney injury | 0.900 | 0.00 | HK2 cells | proposed | N/A |
| Transcriptome sequencing of cardiac fibroblasts in TFEB overexpressing | exploratory | myocardial infarction | 0.900 | 0.00 | R26-LSL-TFEB+/+; Acta2-cre mic | proposed | N/A |
| Trehalose-induced lysosomal changes and TFEB activation | exploratory | motoneuron degeneration | 0.900 | 0.00 | NSC34 neuroblastoma x spinal c | proposed | N/A |
| Trehalose-induced lysosomal membrane permeabilization and TFEB activat | exploratory | motoneuron degeneration | 0.900 | 0.00 | NSC34 neuroblastoma cells | proposed | N/A |
| TFEB silencing and misfolded protein degradation | exploratory | motoneuron degeneration | 0.880 | 0.00 | NSC34 neuroblastoma x spinal c | proposed | N/A |
| Protein expression analysis and cell migration assays in cardiac fibro | exploratory | cardiac fibrosis | 0.880 | 0.00 | primary cardiac fibroblasts fr | proposed | N/A |
| TFAM knockdown functional analysis | exploratory | acute kidney injury | 0.850 | 0.00 | HK2 cells | proposed | N/A |
| Functional validation of trehalose effects on misfolded protein cleara | exploratory | motoneuron degeneration diseas | 0.850 | 0.00 | cell models expressing misfold | proposed | N/A |
| ChIP-qPCR validation of TFEB binding to Thbs1 promoter | exploratory | cardiac fibrosis | 0.850 | 0.00 | mouse cardiac fibroblasts | proposed | N/A |
| Trehalose analog testing for autophagy induction | exploratory | motoneuron degeneration | 0.820 | 0.00 | NSC34 neuroblastoma x spinal c | proposed | N/A |
| TFAM and mtDNA analysis in AKI patients | clinical | acute kidney injury | 0.800 | 0.00 | human patients | proposed | N/A |
| s:** - Test MCU overexpression specifically in layer II neurons in hea | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $200,000 |
| Proposed experiment from debate on Mitochondrial transfer between astr | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protec | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $160,000 |
| Exercise-BDNF-Mitophagy Biomarker Study in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Ferroptosis Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| GLP-1 Agonist Neuroprotection Mechanism in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Melatonin attenuates sepsis-induced acute kidney injury by promoting mitophagy t [PMID:37651673] | Deng Z, He M, Hu H, Zhang W, Zhang Y, Ge | Autophagy | 2024 | 1 |
| TFAM is an autophagy receptor that limits inflammation by binding to cytoplasmic [PMID:38783142] | Liu H, Zhen C, Xie J, Luo Z, Zeng L, Zha | Nat Cell Biol | 2024 | 1 |
| Mitochondrial-derived damage-associated molecular patterns amplify neuroinflamma [PMID:35233090] | Lin MM, Liu N, Qin ZH, Wang Y | Acta Pharmacol Sin | 2022 | 1 |
| Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic [PMID:33408785] | Zhao M, Wang Y, Li L, Liu S, Wang C, Yua | Theranostics | 2021 | 1 |
| Mitochondrial DNA copy number in human disease: the more the better? [PMID:33314045] | Filograna R, Mennuni M, Alsina D, Larsso | FEBS Lett | 2021 | 1 |
| Mitochondrial DNA stress triggers autophagy-dependent ferroptotic death. [PMID:32186434] | Li C, Zhang Y, Liu J, Kang R, Klionsky D | Autophagy | 2021 | 1 |
| Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Protein [PMID:41900026] | Jamerlan A, Hulme J | Molecules (Basel, Switzerland) | 2026 | 0 |
| Butyrate extends health and lifespan in mice with mitochondrial deficiency. [PMID:41826362] | ["Gaband\u00e9-Rodr\u00edguez E", "G\u00 | Nature communications | 2026 | 0 |
| Vav-iCre-Mediated Deletion of TFAM Is Not Recoverable and Is Consistent with Emb [PMID:41898789] | ["Ghosh R", "Shakur E", "Yousefzadeh M"] | Genes | 2026 | 0 |
| NRIP1 co-activates nuclear translocated FOXO3 to upregulate TFAM expression and [PMID:41888517] | ["Zha Y", "Huang H", "Liu Y", "Wan M", " | Cell death discovery | 2026 | 0 |
| miR-137-5p-Loaded Milk-Derived Small Extracellular Vesicles Modulate Oxidative S [PMID:41754992] | ["G\u00f6n\u00fcll\u00fc S", "Ayd\u0131n | Pharmaceutics | 2026 | 0 |
| Mammalian lipophagy: process and function. [PMID:41681129] | Zhao R, Dai E, Kang R, Liu J, Klionsky D | Autophagy | 2026 | 0 |
| Ginseng stem and leaf saponins attenuates pulmonary fibrosis by regulating TFAM- [PMID:41911987] | Chen Y, Hu L, Fu Q, Chen H, Jiang Z, Li | Journal of ethnopharmacology | 2026 | 0 |
| PSAT1 inhibits mTORC1 activation by preventing Rag heterodimer formation in lung [PMID:40702660] | Liu Y, Cheng Z, Zhang J, Zhang Y, Zhao T | Autophagy | 2026 | 0 |
| Electroacupuncture regulates neuronal ferroptosis and ferritinophagy through lys [PMID:41272418] | Tang B, Xu X, Zhao W, Zhou Q, Du G et al | J Cereb Blood Flow Metab | 2026 | 0 |
| Nanocarrier-enhanced simvastatin modulates AMPK-ULK1 pathway and oxidative stres [PMID:41314452] | Afify AM, El-Sayed EK, Ismail A, Nofal S | Eur J Pharmacol | 2026 | 0 |
| Macrophage PD-1 regulates energy expenditure and metabolic dysfunction under imm [PMID:41380676] | Wu MM, Yang YC, Hu ZQ, Chang JY, Xiao H | Cell Metab | 2026 | 0 |
| Maspardin/SPG21 controls lysosome motility and TFEB phosphorylation through RAB7 [PMID:41400694] | Jacqmin T, Gilis F, Albert M, Gaussin JF | J Cell Biol | 2026 | 0 |
| Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothe [PMID:41410033] | Du W, Ringer M, Desai D, Khandakar GI, T | Circulation | 2026 | 0 |
| Proteotoxic stress triggers TFEB- and TFE3-mediated autophagy and lysosomal biog [PMID:41450115] | Zhu Z, Yang J, Montefusco S, Xia S, Ou J | Autophagy | 2026 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.61 · 2026-04-21
closed · Rounds: 4 · Score: 0.73 · 2026-04-21
closed · Rounds: 4 · Score: 0.60 · 2026-04-21
closed · Rounds: 4 · Score: 0.30 · 2026-04-21
closed · Rounds: 4 · Score: 0.50 · 2026-04-20
closed · Rounds: 4 · Score: 1.00 · 2026-04-20
closed · Rounds: 4 · Score: 0.95 · 2026-04-03
Hypotheses and analyses mentioning TF in their description or question text
Score: 0.690 · neurodegeneration · 2026-04-21
**Molecular Mechanism and Rationale** The transcription factor EB (TFEB) and its closely related family member TFE3 rep
Score: 0.679 · neuroscience · 2026-04-22
**Molecular Mechanism and Rationale** The transcription factor EB (TFEB) represents a master regulatory node in cellula
Score: 0.677 · neurodegeneration · 2026-04-04
## Mechanistic Overview Cell-Type Specific TFEB Modulation starts from the claim that modulating TFEB within the disease
Score: 0.650 · neurodegeneration · 2026-04-21
## Mechanistic Overview mTORC1 displacement from lysosomal surface enables calcineurin access to TFEB starts from the cl
Score: 0.647 · neurodegeneration · 2026-04-02
## Mechanistic Overview Mitochondrial SPM Synthesis Platform Engineering starts from the claim that modulating ALOX5 wit
Score: 0.633 · neurodegeneration · 2026-04-21
## Mechanistic Overview G3BP1 NTF2L Domain-Mediated mRNP Scaffold Creates Core Exclusion Zone for Autophagy Receptors st
Score: 0.629 · neurodegeneration · 2026-04-02
## Mechanistic Overview Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring starts from the claim that m
Score: 0.624 · neurodegeneration · 2026-04-25
Integrated stress response factors redirect transcription and chromatin regulation away from tau expression during acute
Score: 0.622 · neurodegeneration · 2026-04-02
## Mechanistic Overview TFEB-PGC1α Mitochondrial-Lysosomal Decoupling starts from the claim that modulating TFEB within
Score: 0.622 · Alzheimer's disease · 2026-04-07
## Mechanistic Overview Optogenetic viral vector delivery via tFUS-mediated blood-brain barrier opening to restore hippo
Score: 0.619 · neurodegeneration · 2026-04-04
## Mechanistic Overview Lysosomal pH Restoration Upstream of TFEB starts from the claim that modulating ATP6V1A within t
Score: 0.609 · neurodegeneration · 2026-04-04
## Mechanistic Overview Temporal TFEB Modulation Therapy starts from the claim that modulating TFEB within the disease c